XML 36 R21.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Equity-Based Compensation | 12 Months Ended
--- | ---
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Equity-Based Compensation | Equity-Based Compensation We have equity-based compensation plans that authorize the issuance of equity-based awards for shares of Class A and Class B common stock to directors, officers and key employees. Equity-based compensation grants are designed to reward long-term contributions to Moog and provide incentives for recipients to remain with Moog. On February 15, 2017, shareholders approved the Employee Stock Purchase Plan ("ESPP"). The ESPP allows for qualified employees (as defined in the plan) to purchase our common stock at a discounted price. The maximum discounted purchase price of a share of our common stock is 85% of the fair market value at the lower of the beginning or the end of the semi-annual offering period. On January 7, 2015, shareholders approved the 2014 Long Term Incentive Plan ("2014 Plan"). The 2014 Plan authorizes the issuance of a total of 2,000,000 shares of either Class A or Class B common stock. The 2014 Plan is intended to provide a flexible framework that permits the development and implementation of a variety of stock-based programs that base awards on key performance metrics as well as align our long term incentive compensation with our peers and shareholder interests. During 2017, we granted awards in the form of stock appreciations rights (SARs), performance-based restricted stock units (PSUs) and restricted stock awards (RSAs). The compensation cost for employee and non-employee director share-based compensation programs for all current and prior year awards granted are as follows:
|  | 2017 |  | 2016 |  | 2015
Stock appreciation rights |  | $ | 3,045 |  |  | $ | 2,482 |  |  | $ | 4,955 |
Performance-based restricted stock units |  | 978 |  |  | 755 |  |  | — |
Restricted stock awards |  | 480 |  |  | — |  |  | — |
Employee stock purchase plan |  | 74 |  |  | — |  |  | — |
Stock options |  | 5 |  |  | 34 |  |  | 119 |
Total compensation cost before income taxes |  | $ | 4,582 |  |  | $ | 3,271 |  |  | $ | 5,074 |
Income tax benefit |  | $ | 1,567 |  |  | $ | 1,184 |  |  | $ | 1,913 |
In 2017 we adopted ASU no. 2016-09, “Improvements to Employee Share-Based Payment Accounting”, and as a result we derive a tax deduction measured by the excess of the market value over the grant price on the date stock-based awards are exercised. The tax benefit from award exercises was $2,222 for 2017 and was recognized as a discrete tax benefit through a reduction of income tax expense. Previously these benefits were recognized as additional paid-in capital and are included in the consolidated statements of cash flows as a financing activity. Stock Appreciation Rights and Stock Options The fair value of SARs granted was estimated on the date of grant using the Black-Scholes option-pricing model. The following table provides the range of assumptions used to value awards and the weighted-average fair value of the awards granted.
|  | 2017 |  | 2016 |  | 2015
Expected volatility |  | 27% - 29% |  |  | 24% - 29% |  |  | 24% - 38% |
Risk-free rate |  | 1.7% - 1.8% |  |  | 1.4% - 1.8% |  |  | .9% - 1.9% |
Expected dividends |  | — | % |  | — | % |  | — | %
Expected term |  | 5-6 years |  |  | 4-6 years |  |  | 3-7 years |
Weighted-average fair value of awards granted |  | $ | 21.20 |  |  | $ | 18.24 |  |  | $ | 28.71 |
To determine expected volatility, we generally use historical volatility based on daily closing prices of our Class A and Class B common stock over periods that correlate with the expected terms of the awards granted. The risk-free rate is based on the United States Treasury yield curve at the time of grant for the appropriate expected term of the awards granted. Expected dividends are based on our history and expectation of dividend payouts. The expected term of equity-based awards is based on vesting schedules, expected exercise patterns and contractual terms. The number of shares received upon the exercise of a SAR is equal in value to the difference between the fair market value of the common stock on the exercise date and the exercise price of the SAR. The term of a SAR may not exceed ten years from the grant date. Options outstanding as of September 30, 2017 consisted of both incentive options and non-qualified options. Options become exercisable over periods not exceeding ten years. The exercise price of SARs and options, determined by a committee of the Board of Directors, may not be less than the fair value of the common stock on the grant date. SARs and options are as follows:
Stock Appreciation Rights |  | Number of Awards |  | Weighted- Average Exercise Price |  | Weighted- Average Remaining Contractual Life |  | Aggregate Intrinsic Value
Outstanding at October 1, 2016 |  | 1,467,219 |  |  | $ | 47.97 |  |  |  |  |
Granted in 2017 |  | 176,000 |  |  | 71.65 |  |  |  |  |
Exercised in 2017 |  | (463,926 | ) |  | 41.36 |  |  |  |  |
Expired in 2017 |  | (6,002 | ) |  | 74.38 |  |  |  |  |
Forfeited in 2017 |  | (4,999 | ) |  | 70.94 |  |  |  |  |  |
Outstanding at September 30, 2017 |  | 1,168,292 |  |  | $ | 53.93 |  |  | 5.6 years |  | $ | 34,381 |
Exercisable at September 30, 2017 |  | 863,358 |  |  | $ | 48.34 |  |  | 4.6 years |  | $ | 30,280 |
Stock Options |  |  |  |  |  |  |  |
Outstanding at October 1, 2016 |  | 118,098 |  |  | $ | 41.02 |  |  |  |  |
Exercised in 2017 |  | (93,416 | ) |  | 40.64 |  |  |  |  |
Outstanding at September 30, 2017 |  | 24,682 |  |  | $ | 42.45 |  |  | 0.2 years |  | $ | 1,011 |
Exercisable at September 30, 2017 |  | 21,788 |  |  | $ | 42.45 |  |  | 0.2 years |  | $ | 893 |
The aggregate intrinsic value in the preceding tables represents the total pre-tax intrinsic value, based on our closing price of Class A common stock of $83.43 and Class B common stock of $83.16 as of September 30, 2017. That value would have been effectively received by the option and SAR holders had all option and SAR holders exercised their options and SARs as of that date. The intrinsic value of awards exercised and fair value of awards vested are as follows:
|  | 2017 |  | 2016 |  | 2015
Stock Appreciation Rights |  |  |  |  |  |
Intrinsic value of SARs exercised |  | $ | 13,363 |  |  | $ | 865 |  |  | $ | 14,566 |
Total fair value of SARs vested |  | $ | 4,044 |  |  | $ | 5,876 |  |  | $ | 5,424 |
Stock Options |  |  |  |  |  |
Intrinsic value of options exercised |  | $ | 2,835 |  |  | $ | 4,100 |  |  | $ | 14,205 |
Total fair value of options vested |  | $ | 66 |  |  | $ | 947 |  |  | $ | 981 |
As of September 30, 2017, total unvested compensation expense associated with SARs amounted to $2,964 and will be recognized over a weighted-average period of two years. Performance-Based Restricted Stock Units PSU awards consist of shares of our stock which are payable upon the determination that we achieve certain established performance targets and can range from 0% to 200% of the targeted payout based on the actual results. PSU's granted in 2017 have a performance period of three years. The fair value of each PSU granted is equal to the fair market value of our common stock on the date of grant. PSUs granted generally have a three year period cliff vesting schedule; however, according to the grant agreements, if certain conditions are met, the employee (or beneficiary) will receive a prorated amount of the award based on active employment during the service period. PSUs are as follows:
Performance-Based Restricted Stock Units |  | Number of Awards |  | Weighted- Average Grant Date Fair Value
Nonvested at October 1, 2016 |  | 38,050 |  |  | $ | 64.95 |
Granted in 2017 |  | 40,700 |  |  | 71.65 |
Forfeited in 2017 |  | (6,000 | ) |  | 68.63 |
Nonvested at September 30, 2017 |  | 72,750 |  |  | $ | 68.39 |
As of September 30, 2017, total unvested compensation expense associated with nonvested PSUs amounted to $2,348 and will be recognized over a weighted-average period of two years. Restricted Stock Awards The fair value of each RSA granted is equal to the fair market value of our common stock on the date of grant. These shares are vested upon grant. There were 6,696 RSAs granted and vested in 2017 at a weighted-average price of $71.65. As of September 30, 2017, the fair value of the RSAs vested is $480.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration